多药耐药蛋白2
运输机
基质(水族馆)
化学
有机阴离子转运蛋白1
药理学
内科学
医学
ATP结合盒运输机
生物化学
生物
基因
生态学
作者
Izna Ali,Jason R. Slizgi,Josh Kaullen,Marija Ivanović,Mikko Niemi,Paul W. Stewart,A. Sidney Barritt,Kim L. R. Brouwer
摘要
The expression of hepatic transporters, including organic anion transporting polypeptides (OATPs) and multidrug resistance‐associated proteins (MRPs), is altered in nonalcoholic steatohepatitis (NASH); however, functional data in humans are lacking. In this study, 99m Tc‐mebrofenin (MEB) was used to evaluate OATP1B1/1B3 and MRP2 function in NASH patients. Healthy subjects ( n = 14) and NASH patients ( n = 7) were administered MEB (∼2.5 mCi). A population pharmacokinetic model was developed to describe systemic and hepatic MEB disposition. Study subjects were genotyped for SLCO1B1 variants. NASH increased systemic and hepatic exposure (median ± 2 SE, healthy vs. NASH) to MEB (AUC 0‐300,blood : 1,780 ± 242 vs. 2,440 ± 775 μCi*min/L, P = 0.006; AUC 0‐180,liver : 277 ± 36.9 vs. 433 ± 40.3 kcounts*min/sec, P < 0.0001) due to decreased biliary clearance (0.035 ± 0.008 vs. 0.017 ± 0.002 L/min, P = 0.0005) and decreased V central (11.1 ± 0.57 vs. 6.32 ± 1.02 L, P < 0.0001). MEB hepatic CL uptake was reduced in NASH and also in healthy subjects with SLCO1B1 *15/*15 and *1A/*15 genotypes. The pharmacokinetics of drugs that are OATP1B1/1B3 and MRP2 substrates may be substantially altered in NASH.
科研通智能强力驱动
Strongly Powered by AbleSci AI